Canaccord Genuity Maintains Buy on Guardant Health, Lowers Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Kyle Mikson maintains a Buy rating on Guardant Health (NASDAQ:GH) but lowers the price target from $45 to $30.

April 29, 2024 | 2:37 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Canaccord Genuity maintains a Buy rating on Guardant Health but lowers the price target from $45 to $30.
While the maintenance of a Buy rating suggests continued confidence in Guardant Health's fundamentals and potential growth, the reduction in the price target could reflect adjustments in valuation metrics, market conditions, or company-specific factors. This mixed signal might lead to short-term volatility in the stock as investors reassess their expectations based on the new price target.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100